NewAmsterdam Pharma Q2 EPS $(0.15) Beats $(0.46) Estimate, Sales $19.145M Beat $2.235M Estimate
Benzinga Newsdesk 1 year ago
EarningsEarnings BeatsNews
NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.46) by 67.39 percent. This is a 63.41 percent increase over losses of $(0.41) per share
NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.46) by 67.39 percent. This is a 63.41 percent increase over losses of $(0.41) per share from the same period last year. The company reported quarterly sales of $19.145 million which beat the analyst consensus estimate of $2.235 million by 756.63 percent. This is a 740.06 percent increase over sales of $2.279 million the same period last year.